BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lucendo AJ. Pharmacological treatments for eosinophilic esophagitis: current options and emerging therapies. Expert Rev Clin Immunol 2020;16:63-77. [PMID: 31842634 DOI: 10.1080/1744666X.2019.1705784] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Kanikowska A, Janisz S, Mańkowska-Wierzbicka D, Gabryel M, Dobrowolska A, Eder P. Management of Adult Patients with Gastrointestinal Symptoms from Food Hypersensitivity-Narrative Review. J Clin Med 2022;11. [PMID: 36555942 DOI: 10.3390/jcm11247326] [Reference Citation Analysis]
2 Besse JA, Osswald GA, Ballaban AY, Caldwell JM, Rothenberg ME. EGIDExpress: An Interactive Shiny Web App to Visualize and Share Large Biological Datasets.. [DOI: 10.1101/2022.10.03.510709] [Reference Citation Analysis]
3 Duclaux-loras R, Belot A. Les biothérapies en pédiatrie. Perfectionnement en Pédiatrie 2022;5:193-201. [DOI: 10.1016/j.perped.2022.07.035] [Reference Citation Analysis]
4 Patel N, Goyal A, Thaker A, Troendle D, Parrish C. A Case Series on the Use of Dupilumab for Treatment of Refractory Eosinophilic Gastrointestinal Disorders. J Pediatr Gastroenterol Nutr 2022;75:192-5. [PMID: 35666881 DOI: 10.1097/MPG.0000000000003512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Lucendo AJ, Santander C, Savarino E, Guagnozzi D, Pérez-Martínez I, Perelló A, Guardiola-Arévalo A, Barrio J, Elena Betoré-Glaria M, Gutiérrez-Junquera C, Ciriza de Los Ríos C, Racca F, Fernández-Fernández S, Blas-Jhon L, Lund Krarup A, de la Riva S, Naves JE, Carrión S, Rodríguez Oballe JA, García-Morales N, Tamarit-Sebastián S, Navarro P, Arias Á, Laserna-Mendieta EJ. EoE CONNECT, the European Registry of Clinical, Environmental, and Genetic Determinants in Eosinophilic Esophagitis: rationale, design, and study protocol of a large-scale epidemiological study in Europe. Therap Adv Gastroenterol 2022;15:17562848221074204. [PMID: 35126668 DOI: 10.1177/17562848221074204] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
6 Tamarit-sebastian S, Ferrer-soler FM, Lucendo AJ. Current options and investigational drugs for the treatment of eosinophilic esophagitis. Expert Opinion on Investigational Drugs. [DOI: 10.1080/13543784.2022.2033207] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Feo-Ortega S, Lucendo AJ. Evidence-based treatments for eosinophilic esophagitis: insights for the clinician. Therap Adv Gastroenterol 2022;15:17562848211068665. [PMID: 35069803 DOI: 10.1177/17562848211068665] [Reference Citation Analysis]
8 Franceschini L, Macchiarelli R, Biviano I, Farsi A. Eosinophilic Esophagitis Onset Despite Six Years' Treatment With Omalizumab in an Asthmatic Patient: No Protective Effect for Anti-IgE Therapy? Am J Gastroenterol 2021;116:1560. [PMID: 33852452 DOI: 10.14309/ajg.0000000000001213] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Lucendo AJ. Nutritional approach to eosinophilic esophagitis: which diet and when. Minerva Gastroenterol (Torino) 2022;68:49-59. [PMID: 33267566 DOI: 10.23736/S2724-5985.20.02797-X] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Laserna-Mendieta EJ, Casabona S, Guagnozzi D, Savarino E, Perelló A, Guardiola-Arévalo A, Barrio J, Pérez-Martínez I, Lund Krarup A, Alcedo J, de la Riva S, Rey-Iborra E, Santander C, Arias Á, Lucendo AJ; EUREOS EoE CONNECT Research group. Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry. Aliment Pharmacol Ther 2020;52:798-807. [PMID: 32677040 DOI: 10.1111/apt.15957] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 11.7] [Reference Citation Analysis]
11 Oliva S, Azouz NP, Stronati L, Rothenberg ME. Recent advances in potential targets for eosinophilic esophagitis treatments. Expert Rev Clin Immunol 2020;16:421-8. [PMID: 32163308 DOI: 10.1080/1744666X.2020.1742110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]